NFKB1 and metabolic dysfunction-associated steatotic liver disease: Berberine inhibits NLRP3 inflammasome activation and downstream signaling factor expression via the ROS/TXNIP pathway or NF-κB signaling pathway, ultimately inhibiting hepatocyte pyroptosis and attenuating NAFLD and liver fibrosis [64].